Skip to main content
S&P 5007,688.62+1.58%DOW53,356.12+3.03%NASDAQ25,736.51+1.44%BTC$80,787.00+5.07%ETH$2,431.65+7.47%GOLD$4,134.30+1.51%OIL$87.17-1.08%
Smart Investors Daily
SID Premium
AT

NASDAQ · ATHE

Alterity Therapeutics Limited

Healthcare · Biotechnology

$2.44

Down-$0.03 (-1.21%)

Updated Nov 5, 2026, 2:43 AM

SID Score

2.8/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
31.19M
P/E ratio
-4.93
Dividend yield
0.00%
52-week range
$2.01 – $5.89
Volume
131.52K
Avg. volume
14.18K

Price performance · ATHE

ATHE price history

1M range · 0 trading sessions · Daily adjusted prices

ATHE does not have enough price history for the selected period.

Data unavailable

Market data is busy. Please try again shortly.

Latest ATHE news

The latest Smart Investors Daily articles mentioning ATHE.

Stock researchCompany · Overview

ATHE research

Overview

Company profile and research snapshot.

Company profile

Alterity Therapeutics Ltd is a clinical-stage biotechnology company focused on neurodegenerative diseases and the creation of a chemical library of proprietary molecules. Its research and clinical development efforts are focused on Parkinson's disease and related disorders, where it is identifying and developing novel compounds that address the underlying pathology of these disorders by binding and redistributing excess labile iron, reducing alpha-synuclein aggregation, and rescuing neurons in the brain. Its pipeline programs are ATH434-201, ATH434-202, bioMUSE, ATH434, and Drug Discovery. The Group operated in one segment, research and development into Parkinsonian and other neurodegenerative disorders.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
ATHE recent ratings
DateFirmRatingTarget
Aug 12, 2026CANACCORD GENUITYBuy—
Jun 9, 2026CANACCORD GENUITYBuy—
Jun 8, 2026CANACCORD GENUITYBuy—
Jan 5, 2018B. Riley FBRBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 9, 2026

Ather Energy (NSEI:ATHERENERG) Stock Sees Modest Fair Value Lift On Stronger Growth Assumptions

Ather Energy’s analyst fair value estimate has shifted from ₹1,641.4 to about ₹1,697.8, which points to a slightly higher price target in updated models. Analysts link this move to more confident assumptions about how Ather Energy could deliver on its growth plans while still accounting for risk. As you read on, you will see how these changing targets and the latest news flow can help you track the evolving narrative around the stock. Analyst Price Targets don't always capture the full story...

Yahoo · Oct 9, 2026

Alterity Therapeutics to Present at the Canaccord Genuity Drug and Device Conference

MELBOURNE, Australia and SAN FRANCISCO, Oct. 09, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David Stamler, M.D., Chief Executive Officer, will present at the Canaccord Genuity Drug and Device Conference on Monday, October 12, 2026 at 3:50 p.m. AEST in Australia. At the conference, Dr. Stamler will deliver a c

Yahoo · Oct 5, 2026

Alterity Therapeutics Presents New Analyses of ATH434 Phase 2 Data in Multiple System Atrophy at the 2026 International Congress of Parkinson’s Disease and Movement Disorders

ATH434 50 mg significantly slowed functional decline in MSA by approximately 52% versus placebo on the 11-item UMSARS at Week 52 with CSF NfL as a covariate Baseline CSF NfL predicted the rate of functional decline, supporting its use as a severity covariate in Phase 3 MELBOURNE, Australia and SAN FRANCISCO, Oct. 05, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments f

Yahoo · Sep 23, 2026

Alterity Therapeutics CEO speaks with Proactive at the ASX SMIDcaps Conference

Alterity Therapeutics CEO David Stamler talked with Proactive at the ASX Small and Mid-Cap Conference about how it’s developing disease modifying therapies, the neurodegenerative diseases market and what’s next for the company. Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) is a clinical stage biotechnology company dedicated to creating an alternate future for people living with neurodegenerative diseases. The Company is focused on developing disease modifying therapies in Multiple System Atrophy (MSA) and related Parkinsonian disorders. Alterity is preparing to initiate a Phase 3 pivotal trial in MSA, a rare and rapidly progressive disease. ATH434, the Company’s lead asset, has demonstrated clinically meaningful efficacy in a randomised, double-blind, placebo-controlled Phase 2 clinical trial in participants with MSA. Alterity has further reported positive data in its open label Phase 2 clinical trial in participants with advanced MSA. In addition, Alterity has a broad drug discovery platform generating patentable chemical compounds to treat the underlying pathology of neurological diseases. #AlterityTherapeuticsLimited #ProactiveInvestors #DavidStamler #NeurodegenerativeDisease #Biotechnology

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By